SCHEMBL4346544

SCHEMBL4346544

COc1ccc(C(=O)c2cnc(N(C3CCNCC3)S(C)(=O)=O)nc2N)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 9/20 0.44
CDK4 P11802 9/20 0.44
CCND1 P24385 9/20 0.44
CDK2 P24941 9/20 0.44
HPGDS O60760 1/20 0.37
LMNA P02545 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 1/20 0.36
CASK O14936 1/20 0.35
ROCK2 O75116 1/20 0.35
CDKL5 O76039 1/20 0.35
STK10 O94804 1/20 0.35
CDK14 O94921 1/20 0.35
ABL1 P00519 1/20 0.35
EGFR P00533 1/20 0.35
MAK P20794 1/20 0.35
CDK11B P21127 1/20 0.35
TTK P33981 1/20 0.35
CLK1 P49759 1/20 0.35
CLK2 P49760 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4361247 0.89 CDK1 (0.42) CDK1CDK4CCND1CDK2LMNA
SCHEMBL4352658 0.88 CDK1 (0.41) CDK1CDK4CCND1CDK2CASK
SCHEMBL4350748 0.88 CDK1 (0.39) CDK1CDK4CCND1CDK2CASK
SCHEMBL3519635 0.88 CDK2 (0.45) CDK1CDK4CCND1CDK2CDK5
SCHEMBL4351112 0.87 CDK1 (0.50) CDK1CDK4CCND1CDK2HPGDS
SCHEMBL3837574 0.86 CDK2 (0.38) CDK1CDK4CCND1CDK2HPGDS
SCHEMBL4360994 0.86 CDK1 (0.45) CDK1CDK4CCND1CDK2LMNA
SCHEMBL4352681 0.84 CDK1 (0.52) CDK1CDK4CCND1CDK2CASK
SCHEMBL4352515 0.84 CDK1 (0.65) CDK1CDK4CCND1CDK2CASK
SCHEMBL4350391 0.82 CDK1 (0.51) CDK1CDK4CCND1CDK2CASK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US claimed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP claimed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO claimed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 CDK1 6/4885CDK4 1/4885CCND1 32/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 CDK1 6/4885CDK4 1/4885CCND1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.